Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Détails

ID Serval
serval:BIB_663787DE1313
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Périodique
Annals of oncology : official journal of the European Society for Medical Oncology
Auteur(s)
Mazières J., Barlesi F., Filleron T., Besse B., Monnet I., Beau-Faller M., Peters S., Dansin E., Früh M., Pless M., Rosell R., Wislez M., Fournel P., Westeel V., Cappuzzo F., Cortot A., Moro-Sibilot D., Milia J., Gautschi O.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
02/2016
Peer-reviewed
Oui
Volume
27
Numéro
2
Pages
281-286
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1-2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens.
This retrospective cohort study in European centers assessed patients with advanced non-small-cell lung cancer (NSCLC), a known HER2 exon-20 insertion, treated with chemotherapy and/or HER2-targeted drugs.
We identified 101 eligible patients from 38 centers: median age 61 years (range: 30-87), 62.4% women, 60.4% never-smokers. All tumors were adenocarcinomas. Concomitant EGFR mutations, ALK translocations, and ROS translocations were observed in 5, 1, and 1 patients, respectively. The median number of treatment lines was 3 (range: 1-11). The median overall survival was 24 months. Overall response rate (ORR) and the median progression-free survival (PFS) with conventional chemotherapy (excluding targeted therapies) were 43.5% and 6 months in first-line (n = 93), and 10% and 4.3 months in second-line (n = 52) therapies. Sixty-five patients received HER2-targeted therapies: trastuzumab = 57, neratinib = 14, afatinib = 9, lapatinib = 5, T-DM1 = 1. ORR was 50.9% and PFS was 4.8 months with trastuzumab or T-DM1.
This series shows the chemosensitivity of HER2-driven NSCLC, and the potential interest of HER2-targeted agents. Our results should help to define the best therapeutic strategy for these patients and to orient future clinical trials.

Mots-clé
Adenocarcinoma/drug therapy, Adenocarcinoma/genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cohort Studies, Disease-Free Survival, Europe, Female, Humans, Lung Neoplasms/drug therapy, Lung Neoplasms/genetics, Male, Middle Aged, Molecular Targeted Therapy/methods, Quinazolines/therapeutic use, Quinolines/therapeutic use, Receptor Protein-Tyrosine Kinases/genetics, Receptor, Epidermal Growth Factor/genetics, Receptor, ErbB-2/genetics, Retrospective Studies, Trastuzumab/therapeutic use, Treatment Outcome
Pubmed
Open Access
Oui
Création de la notice
11/03/2016 10:12
Dernière modification de la notice
20/08/2019 14:22
Données d'usage